

Facile synthesis of various 2-substituted-4-(2-pyridyl) benzopyran analogues as target potassium channel opener

A. K. Tripathi,* Debaraj Mukherjee, S. Koul, and Subhash C. Taneja

Indian institute of integrative medicines (CSIR), Canal Road, Jammu-180001, India

E-mail: tripathitripathi@rediffmail.com

Abstract

A series of 2-substituted-4-(2-pyridyl)benzopyran analogues **6a-e** have been prepared in 20-34% overall yields by the reductive condensation of 2-substituted-3,4-dihydro-2*H*-1-benzopyran derivatives **5a-e** with pyridine, as a key step.

Keywords: Benzopyran, acetophenone, pyridine, Al/HgCl₂, potassium channel openers

Introduction

4-substituted benzopyran derivatives constitute a class of compounds with application as potassium channel openers, which regulate changes in the intracellular level of adenosine triphosphate (ATP). These channels are closed when intracellular ATP levels are elevated and opened when the level declines, thus linking membrane potential to the metabolic state of the cell.¹ Opening them allows the passage of potassium ions out of the cell, causing transmembrane hyperpolarization which in turn reduces intracellular calcium concentration by a blocking function of voltage-dependent calcium channels and inhibiting intracellular calcium release, resulting in smooth muscle relaxation and antispasmodic action.² The use of potassium channel openers³⁻¹³ may therefore, be valuable in treating disorders caused by smooth muscle contraction, such as hypertension, angina pectoris, asthma,¹⁴ urinary incontinence,¹⁵ and baldness.¹⁶ Additionally, these agents may provide the cells a measure of protection against ischemia, independent of their vasodilating actions,¹⁷ and have antilipidemic effects, lowering low density lipoprotein (LDL) cholesterol and triglycerides while increasing high density lipoprotein (HDL) cholesterol.¹⁸





Figure 1. 4-Substituted benzopyran derivatives¹⁹⁻²⁴ as potassium channel openers.

There are several prototypes of this class of compound (Figure 1) all having a common structural moiety i.e. 4-substituted benzopyran **1-6**.¹⁹⁻²⁴ As part of a program to develop new compounds we decided to prepare 4-(2-pyridyl)-4-hydroxybenzopyran and substituted derivatives as target potassium channel openers.

There are two broad approaches for the synthesis of 4-substituted benzopyrans. The first approach^{18,25} deals with the opening of an epoxide at the 3,4-double bond of the benzopyran nucleus (Scheme 1a) by nucleophilic attack of electron rich heterocycles in the presence of base and dehydration to afford 4-substituted chromenes.




Scheme 1. Literature method for synthesis of 4-hetero-substituted chromenes.

Another strategy²⁶ involves reaction of benzopyran-4-one with Tf₂O followed by concomitant attack of organozinc compounds to displace the resulting triflate affording 4-pyridyl benzopyran analogues (Scheme 1b).

Both the approaches suffer from poor yields and multiple reaction steps. In particular, the second approach requires the presence of electron withdrawing groups such as trifluoromethyl group at the 2-position of the benzopyran ring. Thus, development of a more flexible and direct approach for the construction of a substituted cromakalim is highly desirable considering the potential medicinal value. In continuation of our recent work²⁷ towards the development of novel protocols for the synthesis of substituted benzopyrans for the exploration of potentially biologically active leads, we now report synthesis of various 2-substituted-4-(2-pyridyl) benzopyrans using aluminium amalgam as catalyst in reductive condensation of 2-substituted-2*H*-1-benzopyran derivatives with pyridine as a key step.

Results and Discussion

For the synthesis of 2-substituted-7-hydroxy-benzopyran, the Tripathi-Taneja²⁸ procedure, a modified general procedure for the preparation of benzopyrans, was chosen (Scheme 2).







Reagents and conditions: (i) ZnCl₂, CH₃COOH, heat; (ii) pyrrolidine, ketone substrate, benzene, reflux.


Scheme 2. Synthesis of 2-substituted-7-hydroxy-chromanones.

The 2-substituted-7-hydroxy-chromanones were prepared by the base catalysed condensation of substituted acetophenones with carbonyl compounds to give 2,2-disubstituted-7-hydroxy-benzopyran-4-ones **3a-d** (93-98%). As anticipated, yields in the condensation reaction decreased with sterically more demanding ketones and the highest yield was observed with acetone as carbonyl partner (Table 1)

Table 1. Condensation of acetophenones with carbonyl compounds

Entry	Substrate	Product	R ¹ + R ²	R ³	Yield (%)
1	2	3a		H	98
2	2	3b		H	92
3	2	3c		H	86
4	2	3d		H	83

Methylation of the phenolic group afforded 7-methoxy derivatives **4a-d**. In order to investigate the effect of substituents in the reductive condensation reaction, **4d** was subjected to nitration with silver nitrate and Tf₂O in dichloromethane to afford **4e** in 79% yield. To introduce a pyridyl group at C-4, we resorted to the heterogeneous reductive condensation method reported by Emmert and Asendorf,²⁹ with some modification. Thus the reaction was carried out by condensation of benzopyran with pyridine in the presence of aluminium amalgam [Al/HgCl₂] to afford the desired 4-(2-pyridyl)-substituted benzopyrans **5a-e** (Scheme 3).


















Reagents and conditions: (iii) CH₃I, acetone, K₂CO₃, reflux; (iv) i. AgNO₃, TfAA, DCM; ii, pyridine, HgCl₂-Al, reflux; (v) *p*-TSA, benzene, reflux.

Scheme 3. Synthesis of 4-(2-pyridyl)-4-hydroxy 3,4-dihydro-benzopyran and 4-(2-pyridyl)-2-*H*-benzopyrans.

The 4-(2-pyridyl) chroman derivatives were identified by NMR spectroscopy, e.g. in the ¹H NMR spectrum of compound **5a**, besides the signals for pyridine protons which appeared downfield at δ 6.99, 7.25, 7.60, and 8.53, those for the methylene proton (H3) appeared as two doublets at δ 2.13 & 2.19. The other signals appeared at their anticipated positions.

Table 2. Synthesis of 4-(2-pyridyl) 4-hydroxy-3,4-dihydrobenzopyrans from benzopyran-4-one

Entry	Substrate	Product	R ¹ + R ²	R ³	Yield (%)
1.	3a	4a		H	99
2.	3b	4b		H	97
3.	3c	4c		H	97
4.	3d	4d		H	97
5.	4a	4e		NO ₂	79
6.	4a	5a		H	42
7.	4b	5b		H	40
8.	4c	5c		H	40
9.	4d	5d		H	39
10.	4e	5e		NO ₂	33
11.	5a	6a		H	97
12.	5b	6b		H	96
13.	5c	6c		H	94
18.	5d	6d		H	93
14.	5e	6e		NO ₂	89

The structure corroborated by its mass spectrum which showed the M⁺ peak at *m/z* 286 and characteristic fragment peaks at *m/z* 268 (M⁺-H₂O) and *m/z* 189 (M⁺-pyridine). The structure was further confirmed by its ¹³C-NMR spectrum showing the presence of a quaternary carbon signal at δ 75.5 for C-4. It was observed that electron withdrawing group at C-6 reduced the yield of the coupling reaction to some extent.

Dehydration of compounds **5a-e** with *p*-TSA afforded the desired 4-(2-pyridyl)chromans **6a-e** in good yields. The formation of dehydration products were confirmed by the disappearance of C-3 methylene resonances at δ 2.2-2.7 and the appearance of an H-3 olefinic proton signal at δ 5.80-6.30.

In summary: a series of 2-(7-methoxy-2*H*-cromen-4-yl)pyridines **6a-e** have been prepared by reductive condensation of 2-substituted-3,4-dihydro-2*H*-1-benzopyrans **5** with pyridine. The structures of all new products have been confirmed by elemental analysis and spectral studies (IR, ^1H NMR and Mass Spectrometry). Further biological studies, e.g. cytotoxicity, antihypertensive, potassium channel openers, etc of short listed compounds are in progress and will be reported in due course.

Experimental Section

General. Solvents and other chemicals were of reagent grade and were used without further purification. Laboratory grade solvents were purified and dried by reported methods. All melting points were determined in capillary tubes on a Buchi technical apparatus (BUCHI-510) and are uncorrected. NMR spectra were obtained on Bruker Supercon 200 MHz and 500 MHz instruments and are expressed in δ values downfield from tetramethylsilane (TMS) as the internal standard. Mass spectra were recorded with a JEOL MS-D 300 mass spectrometer. IR spectra (KBr pellet or neat sample) were recorded on Perkin Elmer-377 and Shimadzu IR-435 spectrophotometers. Column chromatography was performed on silica gel (100-200 mesh) and TLC on silica gel 60 F₂₅₄ (Merck). For the visualization of spots either UV or iodine vapour or 10% aqueous sulfuric acid containing 2% ceric ammonium sulfate or 5% ethanolic solution of 2,4-dinitrophenylhydrazine was used. Atomic Absorption spectroscopy of all final compounds were performed in Perkin Elmer A Analyst 800 and below detection level (BDL) of Hg²⁺ ion observed in the range 0.001-0.0006% in all cases.

Synthesis of 2-substituted-4-hydroxy-3,4-dihydro-4-(2-pyridyl)-2*H*-1-benzopyran **5a-e**

General procedure

To a mixture of HgCl₂ (0.037 mole) and freshly prepared aluminium powder heated at 120 °C for 20 minutes was added a mixture of pyridine (1.20 ml) and **5** (0.0080 mol) with vigorous stirring and the contents were refluxed for 1 h. The reaction mixture was cooled and then poured into 6N NaOH solution (20 ml) with vigorous stirring. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with water and finally distilled to give an oily residue. The crude product was chromatographed on silica gel column using petroleum ether:ethyl acetate (80:20) as eluent to give **5** as a semisolid.

Synthesis of 2-substituted-3,4-dihydro-4-(2-pyridyl)-2H-1-benzopyrans 6a-e. General procedure

To a solution of **5** (0.01 mol) in benzene (50 ml) was added *p*-toluenesulfonic acid (0.2 g). The mixture was heated at reflux temperature for 2 h and then cooled to room temperature. The contents of the reaction mixture were extracted with ethyl acetate (3x50 ml); the organic layer was washed with brine (80 ml), dried over sodium sulfate, and concentrated on a rotary evaporator under reduced pressure to give a brick red gummy residue, which on chromatography over a silica gel column using petroleum ether-ethyl acetate (80:20) as eluent yielded **6** as a gummy mass.

2,2-Dimethyl-4-hydroxy-7-methoxy-3,4-dihydro-4-(2-pyridyl)-2H-1-benzopyran 5a.

Analysis : found C 70.21, H 6.63, N 4.70%; C₁₇H₁₉NO₃ requires C 71.50, H 6.71, N 4.91%. IR: 3350, 2900, 1620, 1585, 1500, 1440, 1385, 1370, 1340, 1260, 1240, 1200, 1140, 1110, 1080, 1030, 980, 940, 860, 840, 785, 760, 740 cm⁻¹, ¹H NMR (200 MHz, CDCl₃): δ 1.46 (6H, s, 2xCH₃), 2.49 (2H, s, CH₂), 3.75 (3H, s, OCH₃), 6.43 (2H, m, 6-H & 8-H), 6.67 (1H, d, *J*= 8.5Hz, 5-H), 6.99 (1H, dd, *J*=2.2 & 8.2Hz, 3H-Py), 7.25 (1H, m, 5H-Py), 7.60 (1H, m, 4H-Py), 8.53 (1H, d, *J*=4.4 Hz, 6H-Py). ¹³C NMR (50 MHz, CDCl₃): δ 25.7 (CH₃), 25.8 (CH₃), 51.0 (C-3), 55.5 (OCH₃), 71.0 (C-2), 75.5 (C-4), 102.0 (C-8), 108.8 (C-6), 119.5 (C-9), 121.6 (C-5), 122.5 (C-5 Py), 130.9 (C-3 Py), 137.5 (C-4 Py), 146.9 (C-2 Py), 155.5 (C-10), 160.8 (C-7), 165.7 (C-6 Py). MS *m/z* (%) 285 (M⁺): 285 (2), 284 (27), 268 (22), 253 (25), 232 (35), 211 (100), 196 (27), 191 (6), 189 (11), 160 (76), 143 (13), 116 (25), 89 (65), 63 (26).

2,2-Dimethyl-7-methoxy-4-(2-pyridyl)-2H-1-benzopyran 6a. Analysis for C₁₇H₁₇NO₂ (found C 77.81, H 6.39, N 5.08%, requires C 77.38, H 6.41, N 5.24%). IR: 3350, 2900, 1610, 1600, 1500, 1460, 1439, 1380, 1360, 1290, 1280, 1200, 1140, 1140, 1120, 1040, 985, 895, 840, 800, 780, 740cm⁻¹, ¹H NMR (200 MHz, CDCl₃): δ 1.49 (6H, s, 2xCH₃), 3.77 (3H, s, -OCH₃), 5.80 (1H, s, 3-H), 6.47 (1H, d, *J*=8.5 & 2.Hz, 6-H & 8-H), 7.14 (1H, dd, *J*=2.2 & 8.2Hz, 3H-Py), 7.18 (1H, m, 5H-Py), 7.60 (1H, d, *J*=8.5 Hz, 5-H), 7.62 (1H, m, 4H-Py), 8.65 (1H, d, *J*=4.4 Hz, 6H-Py). ¹³C NMR (50 MHz, CDCl₃): δ 27.7 (2xCH₃), 55.5 (OCH₃), 76.5 (C-2), 102.9 (C-8), 107.0 (C-6), 114.8 (C-3), 123.1 (C-5), 123.6 (C-5 Py), 126.6 (C-3 Py), 129.0 (C-4 Py), 134.1 (C-9), 136.7 (C-2 Py), 146.9 (C-10), 155 (C-7), 161.1 (C-4), 165.7 (C-6 Py). MS *m/z* (%) 268 (M⁺): 268 (46), 254 (100), 239 (11), 225 (11), 213 (20), 199 (19), 186 (9), 163 (16), 89 (18).CDCl₃

2-Ethyl-2-methyl-7-methoxy-3,4-dihydro-4-hydroxy-4-(2-pyridyl)-2H-1-benzopyran-4-one

5b. Analysis for C₁₈H₂₁NO₃ (found C 71.78, H 6.91, N 4.57%, requires C 72.20, H 7.07, N 4.68%). IR: 3300, 2900, 2360, 1590, 1500, 1440, 1380, 1340, 1260, 1200, 1160, 1140, 1110, 1080, 1030, 980, 935, 880, 840, 795, 745 cm⁻¹ ¹H NMR (200 MHz, CDCl₃): δ 0.93 (3H, t, *J*= 6.5Hz, CH₂CH₃), 1.30 (3H, s, CH₃), 1.90 (2H, q, *J*= 6.5Hz, CH₃CH₂), 2.23 (2H, s, C-CH₂-C), 3.76 (3H, s, OCH₃), 6.33 (1H, d, *J*= 2.5Hz, 8-H), 6.41 (1H, dd, *J*= 8.5Hz, 2.5Hz, 6-H), 6.67 (1H, d, *J*= 8.5Hz, 5-H), 6.98-7.4 (2H, m, 3,5H-Py), 7.48-6.93 (1H, m, 4H-Py) 8.58 (1H, d, *J*= 4.5 Hz, 6H-Py). ¹³C NMR (50 MHz, CDCl₃): δ 8.3 (-CH₃), 22.5(-CH₃), 29.4 (-CH₂), 48.8 (C-3), 55.5 (-OCH₃), 70.89 (C-2), 78.14 (C-4), 102.0 (C-8), 108.7 (C-6), 119.7 (C-9), 121.7 (C-5), 122.4 (C-5 Py), 130.8 (C-3 Py), 137.4 (C-4 Py), 146.8 (C-2 Py), 155.6 (C-10), 156.7 (C-4), 166.0 (C-7),

165.0 (C-6 Py). MS m/z (%) 299 (M⁺): 299 (5), 281 (13), 253 (19), 252 (49), 229 (56), 221 (97), 214 (26), 214 (8), 191 (18), 175 (11), 151 (100), 124 (6), 122 (11), 106 (43), 95 (16), 79 (45), 63 (7).

2-Ethyl-2-methyl-7-methoxy-4-(2-pyridyl)-2H-1-benzopyran 6b. Analysis for C₁₈H₁₉O₂N as (found C 76.33, H 6.61, N 4.90%, requires C 76.83, H 6.81, N 4.98%). IR(KBr):2900, 1615, 1595, 1575, 1500, 1460, 1440, 1360, 1320, 1280, 1200, 1160, 1135, 1040, 1000, 880, 840, 800, 780, 740 cm⁻¹, ¹H NMR (200 MHz, CDCl₃): δ 1.03 (3H, t, J = 6 Hz, -CH₂CH₃), 1.46 (3H, s, CH₃), 1.83 (2H, q, J = 6 Hz, CH₂CH₃), 3.76 (3H, s, -OCH₃), 5.80 (1H, s, 3-H), 6.38 (1H, d, J =2.0Hz, 6-H), 6.56 (1H, dd, J = 8.5Hz & 2.5Hz, 8-H), 7.23 (1H, d, J = 8 Hz, 5-H), 7.24 (1H, m, 5H-Py), 7.38 (1H, m, 3H-Py), 7.75 (1H, m, 4H-Py), 8.70 (1H, d, J = 4.5 Hz, 6H-Py). ¹³C NMR (50 MHz, CDCl₃): δ 7.96 (CH₃), 24.80 (CH₃), 33.08 (CH₂), 54.84 (OCH₃), 78.4 (C-2), 102.1 (C-8), 106.0 (C-6), 114.1 (C-3), 122.1 (C-5), 122.9 (C-5 Py), 125.9 (C-3 Py), 127.4 (C-4 Py), 134.0 (C-9), 136.1 (C-2 Py), 149.0 (C-10), 154.7 (C-7), 156.7 (C-4), 160.5 (C-6 Py). MS m/z (%) 281 (M⁺): 281 (17), 266 (25), 252 (100), 237 (8), 222 (13), 203 (9), 194 (14), 180 (16), 166 (8), 155 (9), 126 (8), 89 (6), 78 (12).

2,2-Spirocyclopentyl-7-methoxy-4-hydroxy-4-(2-pyridyl)-3,4-dihydro-2H-1-benzopyran 5c. Analysis for C₁₉H₂₁NO₃ found C 73.42, H 6.67, N 4.77%, requires C 73.29, H 6.80, N 4.5%. IR: 2900, 2360, 1615, 1500, 1430, 1375, 1340, 1280, 1260, 1200, 1160, 1140, 1035, 980, 860, 840, 800 cm⁻¹, ¹H NMR (200 MHz, CDCl₃): δ 1.40-2.16 (8H, m, 4xCH₂), 2.75 (2H, s, CH₂), 3.80 (3H, s, OCH₃), 6.40-6.6 (2H, m, 6 & 8-H), 6.82 (1H, d, J = 8.5Hz, 5-H), 7.13-7.47 (2H, m, 3 & 5H-Py), 7.53-7.9 (1H, m, 4H-Py), 8.70 (1H, d, J = 4.5 Hz, 6H-Py). δ 1.24-1.96 (8H, m, CH₂), 2.26 (2H, s, CH₂), 3.83 (3H, s, OCH₃), 6.35 (1H, d, J =2.5Hz, 8-H), 6.56 (1H, dd, J =9 Hz & J =2 Hz, 6-H), 6.81 (1H, d, J =8.5Hz, 5-H), 7.20 (1H, m 5H-Py), 7.40 (1H, m, 3H-Py), 7.73 (1H, m, 4H-Py), 8.70 (1H, d, J =4 Hz, 6H-Py); ¹³C NMR (50 MHz, CDCl₃): δ 23.5 (-CH₃), 24.5 (-CH₂), 40.0 (-CH₂), 48.6 (C-3), 55.5 (-OCH₃), 70.89 (C-2), 78.14 (C-4), 102.0 (C-8), 108.7 (C-6), 119.7 (C-9), 121.7 (C-5), 122.4 (C-5 Py), 130.8 (C-3 Py), 137.4 (C-4 Py), 146.8 (C-2 Py), 155.6 (C-10), 156.7(C-4), 166.0 (C-7), 165.0 (C-6 Py). MS m/z (%) 311 (M⁺): 311 (4), 293 (29), 264 (40), 233 (56), 215 (31), 203 (25), 151 (100), 132 (12), 106 (39), 78 (84), 69 (14), 63 (14).

2,2-Spirocyclopentyl-7-methoxy-4-(2-pyridyl)-2H-1-benzopyran 6c. A solution of **5c** (3.1 g, 0.01 mol) and *p*-toluenesulphonic acid (0.1 g) in benzene (50 ml) was refluxed for 3 h on a water bath. After cooling to room temperature, the reaction mixture was basified with 5% sodium carbonate solution, washed with water, dried over anhydrous sodium sulphate and finally concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography using petroleum ether:ethyl acetate (80:20) as eluent to give **6c** a gummy mass (2.54 g, yield 87%). Analysis: found C 76.99, H 6.50, N 4.93%; C₁₉H₁₉NO₂ requires C 77.79, H 6.53, N 4.77%. IR: 2900, 2360, 2340, 1605, 1500, 1440, 1370, 1360, 1300, 1260, 120, 1200, 1160, 1145, 1020, 985, 860, 840, 820 cm⁻¹, ¹H NMR (200 MHz, CDCl₃): δ 1.30-2.02 (8H, bm, CH₂), 3.89 (3H, s, OCH₃), 5.90 (1H, s, 3-H), 6.43 (1H, d, J =2 Hz, 8-H), 6.60 (1H, dd, J =8.5 & 2.5 Hz, 6-H), 6.90 (1H, d, J =8.5 Hz, 5-H), 7.25 (1H, m, 5H-Py), 7.43 (1H, m, 3H-Py), 7.78 (1H, m, 4H-Py), 8.78 (1H, d, J =4.39Hz, 6H-Py); ¹³C NMR (50 MHz, CDCl₃): δ 20.1 (-2XCH₂),

28.3 (-CH₂), 39.3 (-2XCH₂), 48.6 (C-3), 55.5 (-OCH₃), 70.89 (C-2), 102.0 (C-8), 108.7 (C-6), 114.7 (C-3), 119.7 (C-9), 121.7 (C-5), 122.4 (C-5 Py), 130.8 (C-3 Py), 137.4 (C-4 Py), 146.8 (C-2 Py), 155.6 (C-10), 156.7(C-4), 166.0 (C-7), 165.0 (C-6 Py); MS *m/z* (%) 293 (M⁺); 293 (22), 258 (76), 225 (52), 195 (39), 143 (63), 124 (48), 106 (22), 71 (18).

2,2-Spirocyclohexyl-7-methoxy-4-hydroxy-4-(2-pyridyl)-3,4-dihydro-2H-1-benzopyran 5d.

Analysis for C₂₀H₂₃O₃ (found C 74.33, H 6.87, N 4.18%, requires C 73.82, H 7.12, N 4.30%). IR: 3365, 2850, 1620, 1600, 1500, 1440, 1340, 1280, 1260, 1200, 1160, 1140, 1085, 1040, 985, 840, 785, 745 cm⁻¹, ¹H NMR (200 MHz, CDCl₃): δ 1.45-1.96 (10H, m, 5xCH₂), 2.26 (2H, s, C-CH₂), 3.83 (3H, s, OCH₃), 6.53-6.66 (2H, m, 6 & 8-H), 6.83 (1H, d, *J*=8.5Hz, 5-H), 7.0-7.43 (2H, m, 3, 5H-Py), 7.73 (1H, m, 4H-Py), 8.63 (1H, d, *J*= 4.5Hz, 6H-Py). ¹³C NMR (50 MHz, CDCl₃): δ 22.4 (CH₂), 22.5 (CH₂), 26.0 (CH₂), 32.9 (CH₂), 38.9 (CH₂), 50.2 (-CH₂), 55.6 (-OCH₃), 70.9 (C-3), 76.6 (C-4), 102.1 (C-8), 108.8 (C-6), 120.2 (C-9), 122.2 (C-5), 126.5 (C-5 Py), 132.5 (C-3 Py), 138.7 (C-4 Py), 147.8 (C-3), 155.2 (C-10), 160.8 (C-7), 165.9 (C-6⁻), MS *m/z* (%) 325 (M⁺); 325 (18), 307 (12), 264 (23), 247 (40), 230 (52), 200 (13), 166 (8), 151 (100), 149 (21), 134 (36), 106 (54), 78(36), 69 (8), 63 (6).

2,2-Spirocyclohexyl-7-methoxy-4-(2-pyridyl)-2H-1-benzopyran 6d.

Analysis for C₂₀H₂₁O₂N (found C 77.93, H 6.76, N 4.49%, requires C 78.15, H 6.89, N 4.56%). IR: 2850, 1620, 1600, 1500, 1460, 1440, 1360, 1320, 1280, 1260, 1200, 1160, 1120, 1040, 1000, 985, 920, 840, 810, 795 cm⁻¹, ¹H NMR (200 MHz, CDCl₃): δ 1.33-2.00 (10H, m, 5xCH₂), 3.87 (3H, s, OCH₃) 5.87 (1H, s, 3-H), 6.40 (1H, d, *J*= 2.5Hz, 8-H), 6.63 (1H, dd, *J*= 8.5 & 2.5Hz, 6-H), 7.20 (1H, d, *J*= 8.5Hz, 5-H), 7.32 (1H, m, 5H-Py), 7.45 (1H, m, 3H-Py), 7.68 (1H, m, 4H-Py), 8.57 (1H, d, *J*=4.4 Hz, 6H-Py), ¹³C NMR(50 MHz, CDCl₃): δ 22.4 (CH₂), 22.5 (CH₂), 26.0 (CH₂), 32.9 (CH₂), 38.9 (CH₂), 50.2 (-CH₂), 55.6 (-OCH₃), 102.1 (C-8), 108.8 (C-6), 114.6 (C-3),120.2 (C-9), 122.2 (C-5), 126.5 (C-5 Py), 132.5 (C-3 Py), 138.7 (C-4 Py), 147.8 (C-3), 155.2 (C-10), 157.2 (C-4), 160.8 (C-7), 165.9 (C-6⁻), MS *m/z* (%) 306 (M⁺); 306 (46), 278 (18), 263 (100), 250 (35), 228 (10), 214 (19), 192 (15), 180 (16), 166 (15), 153 (13), 79 (14), 77 (18), 52 (19).

2,2-Dimethyl-4-hydroxy-6-nitro-7-methoxy-3,4-dihydro-4-(2-pyridyl)-2H-1-benzopyran

(5e). Analysis for C₁₇H₁₈N₂O₅ (found C 60.27, H 5.51, N 8.33%, requires C 61.81, H 5.49, N 8.48%). IR(KBr): 3275, 2940, 1590, 1515, 1440, 1390, 1370, 1330, 1250, 1240, 1210, 1150, 1120, 1060, 1030, 980, 940, 840, 780, 750, 730 cm⁻¹ ¹H NMR(CDCl₃): 1.48 (3H, s, 2xCH₃), 2.66 (2H,s,CH₂), 3.98 (3H,s,OC H₃), 6.26 (1H, s, 8-H), 7.23 (1H, s, 5-H), 7.30 (1H, dd, *J*=2.2 & 8.2Hz, 3⁻-H), 7.41 (1H, m, 5⁻-H), 7.93 (1H, m, 4⁻-H), 8.65 (1H, dd, *J*=2.2 & 8.2Hz, 6⁻-H). ¹³C NMR (50 MHz, CDCl₃): δ 25.8 (CH₃), 25.9 (CH₃), 51.6 (C-3), 55.9 (OCH₃), 72.1 (C-2), 75.8 (C-4), 103.0 (C-8), 116.9 (C-6), 121.9 (C-9), 121.2 (C-5), 122.6 (C-5 Py), 131.7 (C-3 Py), 138.1 (C-4 Py), 147.0 (C-2 Py), 156.4 (C-10), 159.2 (C-7), 166.2 (C-6 Py). MS: *m/z* 330(18), 328(55), 312(100), 267(22), 276(17), 255(10), 240(5), 234(14), 204(11), 188(9), 160(7), 133(13), 107(4).

2,2-Dimethyl-6-nitro-7-methoxy-4-(2-pyridyl)-2H-1-benzopyran 6e.

Analysis for C₁₇H₁₆N₂O₄ (found C 65.17, H 5.20, N 8.83%, requires C 65.38, H 5.16, N 8.99%). IR: 3270, 2940, 1580, 1520, 1440, 1390, 1360, 1330, 1250, 1230, 1210, 1140, 1120,1060, 1020, 980, 930, 840, 770, 750, 735cm⁻¹ ¹H NMR(CDCl₃): 1.48 (6H,s, 2xCH₃), 3.92 (3H, s, OCH₃), 6.30 (1H, s, 3-H) 6.92

(1H, s, 8-H), 7.72 (1H, s, 5-H), 7.25 (1H, dd, J=2.2 & 8.2Hz, 3'-H), 7.35 (1H, m, 5'-H), 7.95 (1H, m, 4'-H), 8.65 (1H, dd, J=2.2 & 8.2Hz, 6'-H). ¹³C NMR (50 MHz, CDCl₃): δ 28.1 (2xCH₃), 55.8 (OCH₃), 77.3 (C-2), 103.8 (C-8), 112.9 (C-6), 115.3 (C-3), 120.8 (C-5), 124.5 (C-5 Py), 127.2 (C-3 Py), 129.4 (C-4 Py), 136.2 (C-9), 138.0 (C-2 Py), 147.0 (C-10), 156.3 (C-7), 161.9 (C-4), 166.6 (C-6 Py). MS: M⁺ at m/z 312(48), 310(32), 294(22), 248(100), 267(12), 238(20), 222(7), 194(15), 170(17), 142(1), 115(18), 89(7).

Acknowledgements

Authors are thankful to CSIR, Delhi for the project grant.

References

1. Gopalakrishnan, M.; Jainis, R. A.; Triggle, D. J. *Drug Dev. Res.* **1993**, *28*, 95.
2. Li H-Y, Hu. C. *Chin. Pharm. J. Beijing* **2005**, *40*, 240.
3. Ellis, G. P.; Lochhart, I. M., Eds, *Chemistry of Heterocyclic Compounds; Chromans and Tocopherols*, Wiley: New York, N. Y., 1981; Vol. 36, p 469.
4. Vicario, J. L.; Badia, D.; Carrillo, L. *Tetrahedron: Asymmetry* **2003**, *14*, 489.
5. Lloyd, J.; Atwal, K. S.; Finlay. H. J.; Nyman. M.; Huynh, T.; Rao, B.; Kover, A.; Schmidt, J.; Vaccaro, W.; Conder, M. L.; West, T. J.; Levesque, P. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 3271.
6. Francisco, P.; Barros, A. I. R. N. A.; Artur Silva, M. S. *J. Biochem. Mol. Toxicology* **2002**, *16*, 220.
7. Edwards, G.; Weston, A. H. *Trends Pharm. Sci.* **1990**, *11*, 417.
8. Joshi, S. S.; Singh, H. *J. Am. Chem. Soc.* **1954**, *76*, 4993.
9. Kabbe, H. J. *Chem. Soc. Rev.* **1997**, *26*, 233.
10. Ashwood, A. V.; Buckingham, R. E.; Cassidy, F.; Evans, J. M.; Faruk, E. A.; Hamilton, T. C.; Nash, D. J.; Willcocks, G.; Stemp, K. *J. Med. Chem.* **1986**, *29*, 2194.
11. Emmert, B. *Chem. Ber.* **1939**, *72b*, 1188.
12. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langlely, I.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. *J. Natl. Cancer Inst.* **1991**, *83*, 757.
13. Debatin, K. M. *Toxicol. Lett.* **2000**, *112/113*, 41.
14. Yoon, Y.; Kim, Y. O.; Lim, N. Y.; Leon, W. Y.; Sung, H. J. *Planta Medica* **1999**, *65*, 532.
15. Kerr, J. F. R.; Wyllie, H. A.; Currie, A. R. *Br. J. Cancer* **1972**, *26*, 239.
16. Dini, L. *Tissue Cell.* **2005**, *37*, 379.
17. Rello, S.; Stockert, J. C.; Moreno, V.; Gamez, A.; Pacheco, M.; Juarranz, A.; Canete, M.; Villanueva, A. *Apoptosis* **2005**, *10*, 201.

18. Ellis, G. P.; *Chemistry of Heterocyclic Compounds; Chromenes, chromanones and chromones*, Eds ,Wiley: New York, N. Y. 1977; Vol. 31, p 1196.
19. Cassidy, F.; Evans, J. M.; Smith, D. M.; Stemp, G.; Edge, C.; Williams, D. *J. Chem. Soc., Chem. Commun.* **1989**, 377.
20. Bergmann, R.; Gericke. R. *J. Med. Chem.* **1990**, 33, 492.
21. Sassen, L. M. A.; DunKer, D. J. G. M.; Gho, B. C. G. *Br. J. Pharmacol.* **1990**, 101, 605.
22. Quagliato, D. A.; Humber, L. G. EPA 0314446, **1989**; *Chem. Abstr.* **1990**, 112, 48798z.
23. Garcia, G.; Di Malta. A.; Soubrie, P. EPA 0370901, **1990**; *Chem. Abstr.* **1990**, 113, 191161n.
24. (a) Attwood, M. R.; Churcher, I.; Dunsdon, R. M.; Hurst, D. N.; Jones, P. S. *Tetrahedron Lett.* **1991**, 32, 811. (b) Attwood, M. R.; Jones, P. S.; Kay, P. B.; Paciorek, P. M.; Redshaw, S. *Life Sci.* **1991**, 48, 803.
25. Ritter, K. *Synthesis* **1993**, 735.
26. Kalinin, V. N. *Synthesis* **1992**, 413.
27. Tripathi, A. K.; Khan, K. R.; Taneja, S. C. *Synth. Commun.* **2003**, 33, 579.
28. Tripathi, A. K.; Koul, S.; Taneja, S. C. *Ind. J. Chem.* **2009**, 48B, 301.
29. Emmert B.; Asendorf, E. *Chem. Ber.* **1939**, 72b, 1188.